Similarly, Acar et al. determined that lung cancer cells that harbour oncogenic mutant EGFR that acquire resistance to the EGFR inhibitor gefitinib develop collateral sensitivity to c-MET inhibitor capmetinib19. Here, MET is linked to lung cancer.